Recurrent Kaposi Sarcoma
8
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma